| 000 | 01993cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030836.0 | ||
| 008 | 130601s2013 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.11.29.Ph.D.2013.Mo.E | ||
| 100 | 0 | _aMona Farag Shabana | |
| 245 | 1 | 0 |
_aEffect of solute carrier organic anion transporter 1B1 (SLCO1B1) and multiple drug resistance 1((MDR1) genotypes on lipid profile of atorvastatin - treated hypercholesterolemic Egyptian patients / _cMona Farag Shabana ; Supervised Amal Anwar Mishriki , Ghada Abdelzaher Hashim , Sameh Wadie Ghali Bakhoum |
| 246 | 1 | 5 | _aعلى صورة الدهون بالدم لمرضى مصريين مصابين بارتفاع الكوليسترول بالدم و يعالجون بعقار (أتورفاستاتين( (MDR1) و (SLCO1B1)تأثير الاشكال الجينية لجينى |
| 260 |
_aCairo : _bMona Farag Shabana , _c2013 |
||
| 300 |
_a110P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Pharmacology | ||
| 520 | _aThe aim of the present study was to evaluate the effect of genetic polymorphisms of SLCO1B1 and MDR1 on the pharmacodynamics of atorvastatin which is the degree of improvement in the lipid profile of patients receiving atorvastatin . We studied 50 patients receiving atorvastatin in a dose of 40 mg once per day for a period of 4 weeks . We used the specific primers for restriction fragment length polymorphism | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAtorvastatin | |
| 653 | 4 | _aHypercholesterolemia | |
| 653 | 4 | _aMDRI | |
| 700 | 0 |
_aAmal Anwar Mishriki , _eSupervisor |
|
| 700 | 0 |
_aGhada Abdelzaher Hashim , _eSupervisor |
|
| 700 | 0 |
_aSameh Wadie Ghali Bakhoum , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c43081 _d43081 |
||